"Hemophilia - Pipeline Review, H2 2012" now available at Fast Market Research

Sept. 23, 2012 - PRLog -- Global Markets Direct's, 'Hemophilia - Pipeline Review, H2 2012', provides an overview of the Hemophilia therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. 'Hemophilia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/463857_hemophilia_pipeline_review_h2_2012.aspx
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Hemophilia.
* A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Hemophilia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Hemophilia therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hemophilia Therapeutic Products under Development, Key Players in Hemophilia Therapeutics, Hemophilia Pipeline Overview, Hemophilia Pipeline, Hemophilia Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hemophilia Overview
Therapeutics Development
An Overview of Pipeline Products for Hemophilia
Hemophilia Therapeutics under Development by Companies
Hemophilia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hemophilia Therapeutics - Products under Development by Companies
Hemophilia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hemophilia Therapeutics Development
Baxter International Inc.
Biogen Idec Inc.
Nektar Therapeutics
VIRxSYS Corporation
Lentigen Corporation
Sangamo BioSciences, Inc.
Novo Nordisk A/S
Dong-A Pharmaceutical Co., Ltd.
GTC Biotherapeutics, Inc.
Octapharma AG
Pfizer Inc.
Bayer AG
PROLOR Biotech, Inc.
ReGenX Biosciences, LLC
PAION AG
Alnylam Pharmaceuticals, Inc
Flamel Technologies S.A.
CSL Limited
Recoly N.V.
EpiVax, Inc.
Inspiration Biopharmaceuticals, Inc.
Discovery Genomics, Inc.
Ascendis Pharma A/S
Hemophilia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Turoctocog Alfa - Drug Profile
Turoctocog Alfa - Drug Profile
Long Lasting rFactor VIII - Drug Profile
Vatreptacog Alfa - Drug Profile
OBI-1 - Drug Profile
Biostate - Drug Profile
Biostate - Drug Profile
CSL689 - Drug Profile
Recombinant Coagulation Factors - Drug Profile
Blood Clotting Factors - Drug Profile
BAX 855 - Drug Profile
Factor VIII - Drug Profile
Factor IX - Drug Profile
ZFP TFs For Hemophilia B - Drug Profile
Human-cl rhFVIII - Drug Profile
NecLip-rFVIIa - Drug Profile
Factor VIII - Drug Profile
Long Lasting rFactor IX - Drug Profile
Solulin - Drug Profile
AMT-060 - Drug Profile
Neumega - Drug Profile
BAY81-8973 - Drug Profile
PF 05280602 - Drug Profile
Hemophilia A Gene Therapy - Drug Profile
Human Factor VIII Proteins - Drug Profile
BAY 86-6150 - Drug Profile
Activated Recombinant Factor VII - Drug Profile
CSL654 - Drug Profile
NN7088 - Drug Profile
AAV2-hFIX - Drug Profile
NN7999 - Drug Profile
Factor VIII - Drug Profile
NN7415 - Drug Profile
Drug For Hemophilia B - Drug Profile
NecLip-pdFVIII - Drug Profile
BAY 94-9027 - Drug Profile
AV513 - Drug Profile
Recombinant Factor VIIa - Drug Profile
Recombinant Factor VIII - Drug Profile
DA-3808 - Drug Profile
HM12260B - Drug Profile
Factor VIIa - Drug Profile
PEG-rFVIII-PI Complex - Drug Profile
Recombinant Factor VIII - Drug Profile
Longer Acting Therapeutic Clotting Proteins - Drug Profile
ALN-APC Program - Drug Profile
MOD-5017 - Drug Profile
CSL627 - Drug Profile
Recombinant FVIII - Drug Profile
Gene Therapy - Drug Profile
Deimmunized FVIII - Drug Profile
rvWF-FP - Drug Profile
Drug For Hemophilia A - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4638...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.